Skip to main content

Table 1 Clinical characteristics of AML patients according to FLT3/ITD status

From: Immunoprofiling of leukemic stem cells CD34+/CD38−/CD123+ delineate FLT3/ITD-positive clones

Patient characteristics

AML pos for FLT3/ITD

AML neg for FLT3/ITD

No. of patients

12

27

Male/female

8/4

17/10

Age at diagnosis, median, (range)

62 (23–73)

69 (23–88)

WBC count at diagnosis × 109/L, median (range)

6.6 (0.9–179)

6.3 (0.7–227)

BM blasts % by morphology, median (range)

72 (26–85)

35 (20–87)

AML de novo/secondary n (%)

9 (75)/3 (25)

23 (85)/4 (15)

FAB classification, n (%)

 Mo

0 (0)

0 (0)

 M1

6 (50)

2 (7)

 M2

1 (8)

10 (37)

 M3

2 (17)

2 (7)

 M4

1 (8)

3 (11)

 M5

1 (8)

4 (15)

 M6

0 (0)

0 (0)

 M7

0 (0)

0 (0)

 Not classified

1 (8)

6 (22)

Cytogenetic risk group, n (%)

Favorable

2 (17)

4 (15)

 Intermediate

10 (83)

13 (48)

 Poor

0 (0)

9 (33)

 Insufficient sample

0 (0)

1 (4)

Induction therapy response, n (%)

 CR

7 (70)

15 (88)

 Failure

3 (30)

2 (12)